MiMedx Group Inc expected to post a loss of 5 cents a share - Earnings Preview
MiMedx Group Inc expected to post a loss of 5 cents a share - Earnings Preview
MiMedx Group Inc MDXG.OQ MDXG.O is expected to show a fall in quarterly revenue when it reports results on July 29 for the period ending June 30 2026
The Marietta Georgia-based company is expected to report a 35.6% decrease in revenue to $63.46 million from $98.61 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for MiMedx Group Inc is for a loss of 5 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for MiMedx Group Inc is $6.00, about 42.9% above its last closing price of $4.20
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.05 | -0.03 | -0.07 | Missed | -154.5 |
Dec. 31 2026 | 0.09 | 0.08 | 0.10 | Beat | 19 |
Sep. 30 2025 | 0.08 | 0.07 | 0.15 | Beat | 114.3 |
Jun. 30 2025 | 0.05 | 0.05 | 0.10 | Beat | 85.2 |
Mar. 31 2025 | 0.06 | 0.06 | 0.06 | Met | 9.1 |
Dec. 31 2024 | 0.07 | 0.07 | 0.05 | Missed | -30.6 |
Sep. 30 2024 | 0.04 | 0.04 | 0.05 | Beat | 13.6 |
Jun. 30 2024 | 0.08 | 0.08 | 0.12 | Beat | 55.6 |
This summary was machine generated July 27 at 21:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on MiMedx
See all newsBrief: Mimedx Announces Favorable Federal Court Ruling In Axiofill® Regulatory Classification Matter
MiMedx Group Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Mimedx To Acquire Sanara Medtech
MiMedx Q2 sales fall less than expected; set to acquire Sanara MedTech
Brief: MiMedx Q2 Sales USD 64.362 Million Vs. IBES Estimate USD 63.5 Million